In this review
Use the ordinary monthly plans as the starting comparison
The monthly semaglutide plan is $146 and tirzepatide is $220. Three-month equivalents are $133 and $201; six-month equivalents are $124 and $183. The account FAQ says billing covers the full cycle, while the package can ship on a different schedule. A smaller equivalent does not mean a smaller first debit. [2] [3] [7]
The bundle describes consultation, prescribed medication, necessary supplies, shipping and follow-up. The payments FAQ adds a $125 consultation fee for sending a prescription to an outside pharmacy. Some treatments can require bloodwork, so confirm those charges and the actual selected invoice rather than treat every possible service as included. [4] [6]
Compare paid terms in the complete treatment-cost planner.
For a flat-rate offer with different linked financial conditions, read our LumiMeds review.
The listed formulas are compounds with different additives
The semaglutide page describes a B12 combination; tirzepatide is described with B3. Those are the seller’s formulations, not Wegovy or Zepbound under different packaging. Neither vitamin addition establishes greater weight loss, better tolerability or clinical equivalence. The actual prescription needs its concentration, volume, quantity and dispensing instructions. [2] [3]
FDA advises using compounded drugs only when a patient’s medical needs cannot be met by an approved drug. Its current guidance addresses dosing, storage and quality risks. The seller’s broad shortage-or-personalization language does not establish that a particular prescription satisfies the current requirements. A lower price is not the clinical reason for compounding. [10]
Keep study products and outcomes distinct with the semaglutide and tirzepatide trial comparison.
Cash payment and state access need separate answers
The payments FAQ says consultations and medicines are not covered by insurance; the general terms describe cash-pay services without claims submission. The basics FAQ permits a patient to submit a claim personally. That is not a promise of reimbursement, an insurance-negotiated price or coverage approval. [5] [6] [9]
The GLP-1 product lists include Mississippi, while the general platform FAQ excludes it. Both also make clear that availability is not nationwide. Obtain confirmation for the exact treatment and physical location before committing, especially where the published lists disagree. The brand name is not evidence of access in all fifty states. [2] [3] [5]
Compare the actual access arrangements in our provider comparisons.
Continuing billing does not guarantee a continuing prescription
Most plans require follow-up every three months, and further information or tests may be needed. A call can be required by state rules; other evaluations may use messaging. The independent provider can decline or change treatment. [4] [9]
The product terms explicitly say subscriptions can renew even if actions needed to maintain an active prescription have not been completed. That makes the distinction consequential: a paid account is not assurance that the next refill can be dispensed. Arrange clinical follow-up and manage the billing separately. [2] [3]
Plan continuity alongside the evidence after treatment stops.
Cancel before processing and keep refund expectations narrow
Product and policy pages specify at least two days before the billing date, whereas the account FAQ refers to two days before processing. Billing is described as one day before the new cycle. Confirm both dates and cancel early enough to avoid relying on the wording difference. [2] [7] [8]
Shipped medicine cannot be returned, including unopened packages. A refund for a non-dispensed subscription portion is discretionary. The payments FAQ is stricter about orders already reviewed or shipped, and general terms allow some evaluation and processing fees to become non-refundable. The selected agreement must settle those boundaries; this is not a money-back trial. [6] [8] [9]
Consider the clinical follow-up question with the nausea evidence.
Compare a different access model before choosing the term
LifeMD is a useful comparison for continuing weight care and branded-medication access support, with care and drug costs considered separately. 50 Stars Health is more relevant to a defined cash-pay compound purchase whose clinical suitability has been established. These services should not be ranked solely by their smallest membership or product number.
The homepage’s up-to-sixteen-percent graphic is labeled self-reported patient data. It is not a controlled estimate of what a new patient will lose on the particular compound. Choose for an appropriate prescription, usable clinical contact and a tolerable commitment, rather than that percentage. [1]
For the branded-access care model, read our LifeMD review.
Understanding the cost
Semaglutide: $146 monthly, $133/month equivalent on three months, $124/month equivalent on six. Tirzepatide: $220, $201 and $183 respectively. Full-cycle payments and shipping frequency differ; confirm the actual enrollment debit and lab/additional-pharmacy costs. Cash pay, without an insurance reimbursement promise. [2] [3] [4] [5] [6] [7]
Build your cost estimateSources
- 50 Stars Health: catalogue and six-month upfront-price qualification
- 50 Stars Health: compounded semaglutide/B12, inclusions and state list
- 50 Stars Health: compounded tirzepatide/B3, inclusions and state list
- 50 Stars Health: consultation format, three-month follow-ups and testing requirements
- 50 Stars Health: general availability, pharmacy description and support hours
- 50 Stars Health: payment, insurance, pharmacy-transfer fee and replacement conditions
- 50 Stars Health: full-cycle billing, shipping schedules and cancellation cutoff
- 50 Stars Health: subscription, returns, replacements and discretionary refunds
- 50 Stars Health: August 17, 2026 terms, independent providers, SevenCells and payment conditions
- FDA: October 1, 2026 concerns with unapproved GLP-1 drugs
This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.